Do you have chronic spontaneous urticaria? Are you having symptoms despite using antihistamines? If so, you may be able to participate in a research study to find out how effective Remibrutinib is in patients with chronic spontaneous urticaria.

Are you 18 years of age and younger than 75 years old? Do you or do you know someone with Peripheral T-cell Lymphoma? Would you be interested in using your own stem cells versus only using chemotherapy infusions? If you have large cell lymphoma (ALCL) ALK-negative, this study may interest you.

The purpose of this research study is to examine Black women's identity expressions within higher education and how this contributes to their persistence. It further examines how these scholars engage modes of Black finesse to overcome visibility challenges, confront intellectual devaluation, leverage their academic advising relationships, and cultivate joy within these spaces.

To examine the relationship of work and unmet healthcare needs among precariously-employed adults, aged 18 to 49, who are living in rural and underserved counties in eastern North Carolina.

Join our study for a new treatment for a type of blood disorder, Myeloproliferative Neoplasms. We are looking for older adults who have recently been diagnosed and who may not be fit for intense treatments. The study involves testing a new medicine to see if it will help. This new medicine is called INCA035784 to them.

Are you an opera singer who has worked in the American opera industry between 2000 and 2025? You may be eligible to participate in a research study about your professional experiences.

Would you like to be more active? Are you interested in knowing how it feels to walk inside compared to outside? Join our study to learn about walking on a treadmill and walking outside. By joining, you may help us learn more about body shape and size. No need to worry, we will guide you through everything! You can earn money for participating.

To evaluate the anti-tumor activity of carboplatin + MIRV in newly diagnosed subjects with advanced-stage (≥ 75%, ≥ 2+) serous EOC as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 imaging response.

Have you been recently diagnosed with T1D? You may be able to participate in a research study for an investigational cell therapy product to see if it is safe for patients with T1D and to see if it helps to slow down the progression of T1D.

In this study, we want to look at how the drug tirzepatide works in patients with endometrial cancer compared to the standard of care treatment. We will be looking at its effect on the progression of the tumor.